Literature DB >> 15118509

A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials.

Mimi Liu1, Carl D Regillo.   

Abstract

PURPOSE OF REVIEW: The purpose of this report is to review recent literature and ongoing clinical trials of the treatment of neovascular age-related macular degeneration. RECENT
FINDINGS: Advances in the understanding of the pathogenesis of age-related macular degeneration and choroidal neovascularization have resulted in the emergence of pharmacotherapies targeting various aspects of angiogenesis. Preliminary results with the new agents have been encouraging. Moreover, longer follow-up and subgroup analyses of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy studies have suggested new potential indications for photodynamic therapy.
SUMMARY: Currently a patient with wet macular degeneration may have multiple investigational options that were unavailable several years ago. Ongoing clinical trials are aimed at determining the long-term safety and efficacy of these new pharmacologic and combination therapy modalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118509     DOI: 10.1097/01.icu.0000122122.24016.f1

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  5 in total

Review 1.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.

Authors:  Nader Rahimi
Journal:  Exp Eye Res       Date:  2006-05-19       Impact factor: 3.467

3.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

4.  Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye.

Authors:  F E Wang; G Shi; M R Niesman; D A Rewolinski; S S Miller
Journal:  Exp Eye Res       Date:  2007-02-11       Impact factor: 3.467

Review 5.  The role of complement in ocular pathology.

Authors:  Nalini S Bora; Purushottam Jha; Puran S Bora
Journal:  Semin Immunopathol       Date:  2008-02-26       Impact factor: 9.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.